To facilitate the elucidation of the genetic events that may play an important role in the development or tumorigenesis of the prostate gland, we have generated a transgenic mouse line with prostate-speci®c expression of Cre recombinase. This line, named PB-Cre4, carries the Cre gene under the control of a composite promoter, ARR 2 PB which is a derivative of the rat prostate-speci®c probasin (PB) promoter. Based on RT-PCR detection of Cre mRNA in PB-Cre4 mice or Cre-mediated activation of LacZ activity in PB-Cre4/R26R double transgenic mice, it is conclusively demonstrated that Cre expression is post-natal and prostatic epithelium-speci®c. Although the Cre recombination is detected in all lobes of the mouse prostate, there is a signi®cant difference in expression levels between the lobes, being highest in the lateral lobe, followed by the ventral, and then the dorsal and anterior lobes. Besides the prostate gland, no other tissues of the adult PB-Cre4 mice demonstrate signi®cant Cre expression, except for a few scattered areas in the gonads and the stroma of the seminal vesicle. By crossing the PB-Cre4 animals with¯oxed RXRa allelic mice, we demonstrate that mice, whose conventional knockout of this gene is lethal in embryogenesis, could be propagated with selective inactivation of RXRa in the prostate. Taken together, the results show that the PBCre4 mice have high levels of Cre expression and a high penetrance in the prostatic epithelium. The PB-Cre4 mice will be a useful resource for genetic-based studies on prostate development and prostatic disease. q
Introduction
The ability to knock out genes in mouse embryonic stem cells has been widely used to study gene function in vivo. Although conventional gene knockouts have shed light on various parameters about the function of many known genes during development (Capecchi, 1989 (Capecchi, , 1994 , they have not achieved the same success in exploring the physiological and pathophysiological roles of genes in mature animals. This limitation is due to the confounding and potentially lethal effects of gene dysfunction during pre-or early post-natal development in standard gene targeting. This approach does not permit control over the timing of gene disruption or allow the subsequent study of genes that lead to early embryonic lethality or premature death. Furthermore, since conventional gene knockouts provide animals that inherit genetic deletions in all cell types, it is often dif®cult to exclude the possibility that abnormal phenotypes observed in adult animals arise indirectly from an underlying developmental defect (Copp, 1995) , or to de®ne in which tissue the targeted gene acts.
Conditional gene knockout techniques provide a means to circumvent some of the limitations of conventional gene knockout. The Cre-loxP recombination system (Abremski and Hoess, 1984) has become a powerful tool for conditional, cell type and tissue-speci®c deletion of genes, and is limited only by the availability and speci®city of the promoter. The bacteriophage site-speci®c DNA recombinase (Cre; Guo et al., 1997) excises intervening DNA sequences located between two unidirectional loxP recognition sequences (`¯oxed'), leaving one loxP site on the linear DNA (Sternberg and Hamilton, 1981) . Cre recombinase has been used successfully to delete endogenous genes or to activate transgenes in mammalian cell culture systems (Sauer and Henderson, 1988) , as well as transgenic mouse models (Akagi et al., 1997) . The implementation of this strategy requires the creation of conditional target alleles in mice also expressing Cre in a cell type-restricted (Gu et al., 1994) and/or inducible manner using tissue-speci®c (Metzger et al., 1995) or inducible promoters (Kuhn et al., 1995) .
While prostate cancer is the most common malignant visceral neoplasm of men, its etiology remains largely unknown and its clinical course is unpredictable (Hanks et al., 1993) . Recent studies focusing on the molecular genetics of prostate cancer (Dong et al., 1997; Ruijter et al., 1999) are turning into a fruitful area of investigation which might provide clues towards understanding the complex biology of prostate cancer. In this regard, it is of paramount importance to derive a Cre recombinase transgenic animal system with robust expression of a biologically active Cre protein in a prostate epithelial cell-speci®c manner. For this end, we selected a rat probasin (PB) promoter to drive expression of the Cre gene. The original PB promoter, including bases from 2426 to 128, was shown to be suf®cient to target gene expression speci®cally to the epithelial cells of the prostate in transgenic mice (Greenberg et al., 1994) . Using this minimum promoter to target gene expression of SV40 large T and small t antigens, a mouse model (TRAMP) for prostate cancer was created (Greenberg et al., 1995) . Subsequently, it was realized that the small PB promoter was lacking important enhancers that would facilitate high levels of gene expression in the prostate. A large (L) fragment of the PB promoter (from 211 500 to 128) was determined to be highly ef®cient for transgene expression in mice (Yan et al., 1997) . This second generation LPB fragment was coupled to SV40 large T antigen (with a deletion to prevent the expression of the small t antigen) which led to the development of a new transgenic line of prostate cancer (Kasper et al., 1998) . The LPB-Tag lines demonstrated a wide range of tumor growth rates. In contrast to the rapid metastasis seen with TRAMP mice, the LPB-Tag transgenic lines rarely metastasized. Since the production of the LPB promoter, a third generation promoter has been made to target high levels of transgene expression speci®cally to the prostate in transgenic mice. This new composite PB promoter construct (ARR 2 PB) is less than 500 bp in size, androgen and glucocorticoid regulated, prostate-speci®c, and targets high level expression in transgenic mice (Zhang et al., 2000) .
In this report, we describe the generation of transgenic mice carrying the Cre gene under the control of the ARR 2 PB, and demonstrate the validity of the model system to selectively delete genes in the prostate epithelium.
Results

Generation of ARR 2 PB-Cre mice
Transgenic animals resulting from the pronuclear injection of the ARR 2 PB-Cre construct in Fig. 1A were evaluated by PCR analysis and the positives identi®ed were con®rmed by Southern blot hybridization (data not shown). Five founder animals were initially identi®ed as having integrated the transgene. Germ line integration was found in animals 4, 5 and 6, and the transgene was passed to offspring in normal Mendelian ratios. Founders 8 and 12 were unable to transmit the transgene due to infertility and lack of germ line integration, respectively. The offspring from the three remaining founders were normal at birth and no abnormalities were observed through adulthood.
To determine if the transgene was appropriately expressed in the prostate, RT-PCR was performed on total RNA isolated from prostate tissue (Fig. 1B) . The three founder lines produced detectable levels of Cre mRNA in the prostate, as evidenced by the expected 500 bp PCR product. The results were not due to any DNA contamination in the samples since no product was obtained in the absence of reverse transcriptase. To determine if there was spurious expression of the transgene, various other tissues (liver, kidney, ductus deferens, testes, seminal vesicles, heart, lung, spleen and brain) from line 4 animals were examined for Cre mRNA expression by RT-PCR. There was no detectable Cre mRNA in these tissues. For illustration, the results obtained from the testes, seminal vesicle, liver and kidney are shown in Fig. 1B . Thus, the ®ndings were consistent with the previously published tissue speci®city of the PB promoter (Greenberg et al., 1994; Yan et al., 1997; Zhang et al., 2000) . These three founder lines were maintained for further analysis of Cre activity.
Tissue-speci®c Cre recombination activity
The ability to produce tissue-speci®c and cell-speci®c gene deletions is dependent on the level of the Cre protein and its subsequent recombination activity. In order to validate the extent and speci®city of Cre expression, each line was cross-bred with the R26R line of transgenic reporter mice carrying a lox-stop transgene (Soriano, 1999) . In the R26R allele, a constitutively active chromosomal gene was manipulated to insert the lacZ gene such that the b-galactosidase protein is produced only following the removal of à stuffer' fragment¯anked by loxP sites. The R26R gene is constitutively expressed in every cell of the embryo and adult, but does not encode a functional LacZ product in the absence of recombination. One important aspect regarding Cre-mediated recombination is that it is a unidirectional and cumulative process. With recombination occurring in a target cell, all progeny of that cell will harbor the recombined allele, even when the promoter driving Cre expression is inactivated. Offspring from each founder were mated to the R26R mouse line, and at 8 weeks of age, the urogenital systems of the double transgenics (lacZ 1 , Cre 1 ) were stained for the presence of LacZ activity using X-gal. Line 4 was the only line to produce suf®cient amounts of Cre protein to result in recombination as determined by LacZ staining. This line was termed PB-Cre4 and was used in all subsequent experiments. We examined the expression pattern of the R26R reporter allele crossed against the PB-Cre 4 transgene in several 8-week-old male mice; all mice showed essentially the same pattern of X-gal staining in the prostate ( Fig. 2A) , while Cre-negative littermate controls did not display X-gal reactivity (Fig.  2B ). In the lateral lobe, almost complete (.95%) labeling of the prostatic epithelium was observed (Fig. 2C) ; approximately 50% of the epithelium of the ventral prostate lobe (Fig. 2D) , and about 10% of the epithelium of the dorsal lobe and 5% of the epithelium of the anterior lobe, were stained (Fig. 2E,F) . There was scattered ®bromuscular stroma staining (approximately 1%) that was detected surrounding the ducts of the dorsal and anterior lobes (Fig. 2E,F) , which was absent in the lateral and ventral lobes. To date, we have assessed the frequency of recombination in animals up to 8 weeks of age. Since the PB promoter is active throughout adult male life, we expect that recombination events in all of the prostatic epithelium will increase with further growth of the animals. It is also expected that the onset and recombination frequency would be accelerated by treatment with androgens.
To determine the tissue speci®city of Cre activity beyond that shown in Fig. 2 , nine other tissues, namely the liver, kidney, lung, heart, spleen, brain, salivary gland, skin and bladder, were removed from male or female double transgenic mice. In addition, the seminal vesicle, epididymas and testes from the males, and the ovary, uterus and mammary gland from the females were examined. Non-prostatic tissues were negative for Cre activity, with the exception of the seminal vesicles, testes and ovaries. There was less than 5% blue staining in the stroma of the seminal vesicles, without any detectable epithelial staining (Fig. 3A) . The age-matched control animals did not produce any X-gal reaction in the seminal vesicle (Fig. 3B ). Since no Cre mRNA was detected in mature seminal vesicles of the double transgenic mice, the discrepancy between X-gal staining and RT-PCR could be related to LacZ activation by recombination at an early time point in the development of the seminal vesicles and a lack of continued Cre gene expression in this tissue in the mature transgenic mice.
Similarly, it is noteworthy that although the gonads of the adult PB-Cre4 mice tested negative for Cre mRNA expression by RT-PCR, a few isolated areas of Cre activity were observed in the gonads of the double transgenics. The testicular activity was characterized by staining of a few short segments of individual tubules (Fig. 4A) . However, it remains to be determined in which cells the recombination occurred. The activity in the testes appeared to be mostly extracellular staining rather than cytoplasmic (Fig. 4A,  inset) . The Cre activity, detected by X-gal, was restricted to a few sites in the ovary (Fig. 4C ) which appeared to be within (Fig. 4C, inset) oocytes, but the number of spots was far less than the number of primary oocytes that reside in the ovary. The lack of reactivity in the testes and ovary of the Cre-negative age-matched littermates is illustrated in Fig.  4B ,D, respectively.
Onset and extent of Cre activity during post-natal development
To determine temporal expression of Cre in prostate development, to date, we have performed X-gal staining on the urogenital system at weekly intervals from newborn animals to 2 weeks of age. In the newborn, the prostatic buds begin the process of branching morphogenesis, and it was found that Cre-mediated recombination was visible at this point in development (Fig. 5A) . Several highly focal areas of X-gal staining could be identi®ed, and by 1 week of age, signi®cant branching had occurred and the ventral lobe could be distinguished from the dorsal/lateral prostate (Fig. 5B ). At this point, the ventral prostate had the most X-gal staining, but staining was still focal, much like in the ventral lobe of the 8-week-old mice. The dorsal/lateral prostate, which is much smaller in size, contained focal staining. By 2 weeks of age, the ventral, lateral and dorsal lobes could be distinguished based on X-gal staining (Fig. 5C ). The lateral prostate was completely stained, indicating that by 2 weeks, the majority of epithelial cells have had recombinational events. Both the ventral and dorsal lobes had focal areas of staining at this point in post-natal development. Double transgenic embryos at 9 and 15 post-coitum days were also examined for X-gal reaction. However, no staining was observed in these embryos (data not shown). The results suggest that Cre expression is highly speci®c for the prostatic epithelium during post-natal development.
Evidence for the utility of the model: conditional mutation of RXRa alleles
There is ample evidence from several lines of study which implicate a role for retinoids in the derivation and maturation of the prostate epithelium. There are two Fig. 2 . X-gal staining of mice harboring the Cre gene and lacZ reporter gene, as well as Cre-negative, age-matched control mice. Tissues from 8-week-old double transgenic mice were used for the detection of Cre recombinase activity using X-gal staining (blue stain). Whole-mount staining of the urogenital system of: (A), transgenic; and (B), control mice. The individual lobes of the prostate are labeled: A, anterior lobes; D, dorsal lobes; L, lateral lobes; V, ventral lobes; other notations indicate: DD, ductus deferens; SV, seminal vesicle; B, bladder; and U, urethra. (C±F) Cross-section of frozen tissues of the lateral, ventral, dorsal and anterior prostate, respectively stained with X-gal. Exclusive epithelial staining in the lateral and ventral is emphasized in insets in (C) and (D), respectively. The presence of staining in ®bromuscular stroma in dorsal and anterior lobes is indicated by arrows in (E) and (F) and emphasized in the corresponding insets. The ductus deferens showed staining in both double transgenic and control mice due to the presence of endogenous b-galactosidase activity. (A,B) Bar, 1 mm; (C,D±F), bar, 0.1 mm; and the bar in the inset of (C) applies equally to all insets and represents 0.01 mm. families of nuclear receptors for retinoid actions: RARs (a, b, g) and RXRs (a, b, g; Leid et al., 1992) . Interestingly, null mutant mice of RARg exhibited squamous metaplasia of the prostate (Lohnes et al., 1993) . RXRa seems to be the heterodimeric partner for RARg (Krezel et al., 1996) . Since conventional knockout of the RXRa gene is lethal in embryogenesis (Chen et al., 1998), we were interested in the production of double transgenic mice with both the Cre transgene and a conditional¯oxed RXRa allele to determine whether there could be a prostatic phenotype in mice with tissue-selective inactivation of RXRa alleles. When male Cre heterozygous PB-Cre4 mice were crossed with female homozygous¯oxed RXRa mice, the intact¯oxed allele was transmitted to 15/15 (100%) of the offspring. However, when a female Cre heterozygous PB-Cre4 mouse was mated with a male¯oxed RXRa homozygous mouse, the intact¯oxed RXRa allele was transmitted in only 8/17 (47%) of the offspring. The remaining nine animals contained a¯oxed out allele, indicating that Cre-mediated recombination had already occurred, resulting in the disruption of one RXRa allele. This could be related to the observed expression of the Cre protein in some eggs, since a few littermate progeny lacking the Cre transgene also showed recombination of the RXRa allele. To determine if sperm containing Cre transgene could initiate the recombination of a¯oxed RXRa allele in the egg, Cre 1 / RXRa (¯oxed/wild-type) male mice were bred with a RXRa (¯oxed/wild-type) female. None of the 39 progeny examined contained a¯oxed out RXRa allele. Thus, the localized Cre activity detected in the testes was not suf®cient to initiate recombination of either maternal or paternal copies of the¯oxed RXRa alleles.
The prostate speci®city of Cre recombination in the conditional RXRa mice was also con®rmed. Male mice carrying the Cre transgene and one¯oxed RXRa were raised to maturity and analyzed for prostate-speci®c RXRa recombination (Fig. 6) . Total DNA from the indicated tissues were subjected to PCR analysis for the¯oxed RXRa gene. The only tissues with evidence of recombination were the dorsal/lateral prostate, ventral prostate and anterior prostate, while other tissues tested, namely the tail, epididymis, seminal vesicle, testes, bladder, liver, heart, kidney, spleen and muscle, showed no detectable recombination. Male mice carrying the Cre transgene and two conditional RXRa alleles were raised to 3 months, to date, demonstrating the utility of the conditional approach for inactivating genes that would have embryonic lethal phenotypes in conventional knockouts.
Discussion
In the present study, we developed a transgenic mouse model in which the Cre transgene is expressed in the prostate epithelium. By breeding with the R26R tester strain (Soriano, 1999) , conclusive evidence was obtained for the prostatic epithelial cell-speci®c expression of Cre in the transgenic mouse line PB-Cre4. The prostatic epithelium of PB-Cre4/R26R mice was stained in X-gal reaction, but there was also noteworthy differential staining. For example, the staining in adult animals was the most intense and uniform in the epithelial cell layer of the lateral lobe of the prostate. The ventral lobe also displayed strong epitheliumspeci®c staining, but it was not homogeneous throughout the lobe. The dorsal and anterior lobes had less staining which appeared to be punctate in nature, and there was also some recombination in a few focal areas of the stroma. This variable, spatial expression pattern may be a characteristic of the native PB gene expression, a point which remains to be examined. When we analyzed the developmental aspects of Cre recombination in the Cre and R26R double transgenic mice, a similarity to PB gene expression was noted, with increasing expression until adulthood. We detected Cre activity in a small number of cells in the prostatic buds in newborn animals. This was 1 week earlier than the ®rst detection of expression of reporter activity in ARR 2 PB-CAT transgenic mice (Zhang et al., 2000) . Another noteworthy observation in our Cre model is the limited but detectable transgene expression in the testes, ovary and seminal vesicles. Previous work on the PB constructs, using 2426/128 PB (Greenberg et al., 1994) , the LPB (Yan et al., 1997) and the ARR 2 PB (Zhang et al., 2000) , have demonstrated that no CAT reporter activity can be detected in the testes or ovaries of transgenic mice. The limited and focal expression of b-gal seen in these tissues after the PB-Cre4 mouse was crossed with the R26R mouse would easily be missed by the less sensitive CAT assay that was performed in the other PB CAT lines. Furthermore, the expression of b-gal is a consequence of¯oxing that could have occurred at an early time point in the development of tissues rather than the continued expression of Cre. This, in fact, is suggested, because in the mature testes, no Cre mRNA was detected by RT-PCR in our model. Since the PB-Cre4 mice represent one founder line, it is impossible to discern whether the expression in a few non-prostatic tissues represents a phenomenon due to the site of integration or whether it re¯ects the actual pattern of transgene expression directed by the ARR 2 PB promoter. Similarly, the detection of a few scattered stromal cells in the seminal vesicle with Cre activity remains unexplained at this time. While the other non-prostatic tissues (liver, kidney, lung, heart, spleen, brain, salivary gland, skin, bladder, uterus and mammary gland) were negative for X-gal staining, the list is not comprehensive. However, the lack of staining in the midgestation embryos argues against the potential that Cremediated activity occurs in a broad range of non-prostatic tissues during development.
The results of the tissue speci®city experiments indicated that the vast majority of Cre activity was localized to the luminal epithelium of the mouse prostate lobes. There was no evidence of Cre expression in the basal cells of any of the prostate lobes examined. This feature of luminal epithelial cell-speci®city could be useful in de®ning the impact of a speci®c gene inactivation in speci®c cell compartments of the prostate compared with conventional gene knockout in the whole prostate.
We document here that the testicular expression appears to have no signi®cant affect on¯oxed genes, and with proper breeding, using Cre 1 male mice, the oocyte Cre-mediated recombination can be avoided. Interestingly, it would, however, be potentially advantageous to transmit the Cre gene through the female in case recombination of both alleles of a¯oxed gene presents a dif®culty. One method to resolve this problem has been to start with a conventional heterozygous knockout so that the Cre has only a single allele to recombine (Trumpp et al., 1999) . In our system, a germlinē oxed out allele would be quite easy to generate. Thus, if there is any question regarding the ability of the Cre to delete both alleles, the solution will be to breed one generation through a Cre 1 female mouse. This would result in a high percentage of offspring with a germline¯oxed allele. Thus, while the transmission of the Cre gene through the PBCre4 male is demonstrated to be the most expeditious way for tissue-speci®c gene disruption, our model also holds the promise of improving the ef®ciency of recombination, if needed, by restricting the genotype to contain a single¯oxed allele via Cre transmission through the female. While we believe that we constructed an important and timely model for prostate-speci®c Cre expression with a clear demonstration of proof-of-principle, it should be noted that during the progress of the work, a report concerning a similar model and using the ®rst generation PB promoter has been published (Maddison et al., 2000) . As it was a short communication, the details needed for evaluation of the extent of usefulness of that model were, however, lacking.
In conclusion, we present evidence for the development of a unique reagent, useful for the scienti®c community at large. This model will certainly be a resource to those who want to selectively manipulate genes of interest in the prostate epithelium during the post-natal development of this gland or tumorigenesis and progression to prostate cancer.
For example, the model could immediately be explored for determining the involvement of several potentially interesting genes (such as FGFs, EGFR3, EGFR4, IGFI, gp130, BRCA1, PTEN, STAT3, etc) in prostate biology and tumorigenesis. All of these genes have been established as conditional alleles, and could be crossed with the PB-Cre4 mice. Additionally, those who may wish to embark on new strategies for the isolation of epithelial cells from the prostate Fig. 5 . Cre expression during post-natal prostate development. X-gal reaction in the whole-mount of the urogenital system of: (A), newborn; (B), 1-week-old; and (C), 2-week-old double transgenic mice. Arrows in (A) point to evidence of Cre recombinase activity in prostatic buds of a newborn mouse. (B) One-weekold mouse prostate shows a signi®cant area of focal staining in the ventral lobe (vp) and some activity in the dorsal/lateral prostate (dlp). (C) Two-week-old mouse prostate displays strong staining in the lateral prostate (lp) and focal staining in the dorsal (dp) and ventral lobes (vp). Whole-mount staining of the prostate of a 2-week-old double transgenic mouse is included for reference, in which DD and B denote the ductus deferens and bladder, respectively. (A±C) Bar, 0.1 mm; (D), bar, 1 mm. Fig. 6 . PCR genotyping of RXRa alleles. Total genomic DNA from different lobes of the prostate and various other tissues from an 8-week-old Cre 1 /RXRa (¯oxed/wild-type) mouse was analyzed by PCR. PCR was performed as described in Section 4, and the alleles of RXRa were differentiated by size. The band at approximately 800 bp is a non-speci®c PCR artifact most pronounced in VP, and also detected in Cre-negative prostate tissues (not shown). F,¯oxed; W, wildtype; Fo,¯oxed out; AP, anterior prostate; VP, ventral prostate; DLP, dorsalateral prostate; SV, seminal vesicle. using genetic-based approaches will bene®t from the Cre model.
Experimental procedures
Transgene construction
To construct a cassette for the production of Cre recombinase transgenic mice, the NotI±XhoI fragment of PB promoter, containing two tandem repeats of the androgen responsive region (ARR 2 PB), was ligated into pCreSV which was digested with the same enzymes as above. The pCreSV vector contained the Cre cDNA, SV40 poly(A) they produced three bands of approximately 1.5 and 1.7 kb, and 500 bp, corresponding to wild-type,¯oxed and¯oxed out RXRa , respectively.
